Director Squires rescinds previous guidelines and clarifies that there is no separate, modified inventorship standard for AI-assisted inventions. Already registered?
Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently ...
Even when legal teams do include women, the judges say they don’t always see or hear them, emphasising that visibility is ...
The Court of Appeal has overturned a ruling that revoked the pharma company’s cholesterol-lowering antibody patent, ...
8 October 2025 A 2021 Supreme Court ruling changed how patent terms are calculated, forcing pharma companies to rethink their ...
Regeneron and Bayer suffered a UK setback as the court followed others in Europe in its interpretation of the so-called SPC ...
14 November 2025 In-house counsel from AstraZeneca, BAT and Novartis say that investing in AI now will pay off in time saved, ...
A regulatory counsel with nine years at the FDA and over two decades of patent experience at a US law firm in Washington DC, ...
The USPTO’s ‘settled expectations’ rule is anything but settled, argues Andrew Zappia of Troutman Pepper Locke. Already ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback